hrHPV Type Detected | HIV-infectedb Participants | HIV-uninfected Participants | HIV-untested Participants | All Participants | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total No. | No. with CIN 2+ | Positive predictive value % (95% CI) | Total No. | No. with CIN 2+ | Positive predictive value % (95% CI) | Total No. | No. with CIN 2+ | Positive predictive value % (95% CI) | Total No. | No. with CIN 2+ | Positive predictive value% (95% CI) | |
Any hrHPV | 42 | 4 | 9.8% (2.7 to 23%) | 193 | 12 | 6.3% (3.3 to 11%) | 20 | 5 | 25% (8.7 to 49%) | 255 | 21 | 8.2% (5.1 to 12%) |
At least one of HPV-16, 18 and 45a | 10 | 1 | 10% (0.25 to 45%) | 43 | 4 | 9.5% (2.7 to 23%) | 5 | 4 | 80% (28 to 99%) | 58 | 9 | 15% (7.3 to 27%) |
HPV-16a | 4 | 0 | 0% (0 to 60%) | 28 | 3 | 11% (2.3 to 28%) | 2 | 2 | 100% (16 to 100%) | 34 | 5 | 15% (5.0 to 31%) |
HPV-18 and/or 45a | 7 | 1 | 14% (0.36 to 58%) | 16 | 1 | 6.3% (0.15 to 30%) | 3 | 2 | 67% (9.4 to 99%) | 26 | 4 | 15% (4.4 to 35%) |
At least one of HPV-31, 33, 35, 39, 51, 52, 56, 58, 59, 66 and 68 but without 16, 18 and 45 | 32 | 3 | 9.1% (1.9 to 24%) | 150 | 8 | 29% (22 to 37%) | 15 | 1 | 13% (1.7 to 40%) | 197 | 12 | 6.1% (3.2 to 10%) |